Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N, Nout RA, Jürgenliemk-Schulz IM, Lutgens LCHW, Jobsen JJ, Haverkort MAD, Mens JWM, Slot A, Wortman BG, de Boer SM, Stelloo E, Verhoeven-Adema KW, Putter H, Smit VTHBM, Bosse T, Creutzberg CL; PORTEC Study Group. Horeweg N, et al. Among authors: stelloo e. J Clin Oncol. 2023 Sep 20;41(27):4369-4380. doi: 10.1200/JCO.23.00062. Epub 2023 Jul 24. J Clin Oncol. 2023. PMID: 37487144 Free PMC article.
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts.
Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Nijman HW, Putter H, Bosse T, Creutzberg CL, Smit VT. Stelloo E, et al. Clin Cancer Res. 2016 Aug 15;22(16):4215-24. doi: 10.1158/1078-0432.CCR-15-2878. Epub 2016 Mar 22. Clin Cancer Res. 2016. PMID: 27006490
Prognostic Integrated Image-Based Immune and Molecular Profiling in Early-Stage Endometrial Cancer.
Horeweg N, de Bruyn M, Nout RA, Stelloo E, Kedziersza K, León-Castillo A, Plat A, Mertz KD, Osse M, Jürgenliemk-Schulz IM, Lutgens LCHW, Jobsen JJ, van der Steen-Banasik EM, Smit VT, Creutzberg CL, Bosse T, Nijman HW, Koelzer VH, Church DN. Horeweg N, et al. Among authors: stelloo e. Cancer Immunol Res. 2020 Dec;8(12):1508-1519. doi: 10.1158/2326-6066.CIR-20-0149. Epub 2020 Sep 30. Cancer Immunol Res. 2020. PMID: 32999003 Clinical Trial.
Microcystic elongated and fragmented (MELF) pattern of invasion: Molecular features and prognostic significance in the PORTEC-1 and -2 trials.
van den Heerik ASVM, Aiyer KTS, Stelloo E, Jürgenliemk-Schulz IM, Lutgens LCHW, Jobsen JJ, Mens JWM, van der Steen-Banasik EM, Creutzberg CL, Smit VTHBM, Horeweg N, Bosse T. van den Heerik ASVM, et al. Among authors: stelloo e. Gynecol Oncol. 2022 Sep;166(3):530-537. doi: 10.1016/j.ygyno.2022.06.027. Epub 2022 Jul 13. Gynecol Oncol. 2022. PMID: 35840357 Free article.
Prognostic significance of POLE proofreading mutations in endometrial cancer.
Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL, Bosse T. Church DN, et al. Among authors: stelloo e. J Natl Cancer Inst. 2014 Dec 12;107(1):402. doi: 10.1093/jnci/dju402. Print 2015 Jan. J Natl Cancer Inst. 2014. PMID: 25505230 Free PMC article.
32 results